Regioselective synthesis of 2-substituted 3-diarylmethylenylpiperidines
摘要:
A simple three-step synthetic routes toward 2-substituted 3-diarylmethylenylpiperidines 7 (Y = CN) and 8 (Y = allyl) starting with 3-diarylmethylenylpiperidines 9 is described. The process was carried out by the bromomethoxylation of skeleton 9 with NBS in MeOH at reflux for 2 h, regioselective alpha-dehydrobromination with DBU in THF at reflux for 10 h, and BF3-OEt(2)catalyzed cross-coupling of the corresponding enamine with trimethylsilyl-based nucleophiles (TMS-Y) in DCM at rt for 2 h. alpha-Amino ester 18 and beta-amino acid 19 are also synthesized via the simple three-step synthetic protocol. (C) 2011 Elsevier Ltd. All rights reserved.
N-substituted piperidines and their use as pharrmaceuticals
申请人:Yao Wenqing
公开号:US20060004049A1
公开(公告)日:2006-01-05
The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
N-substituted piperidines and their use as pharmaceuticals
申请人:Incyte Corporation
公开号:US08071624B2
公开(公告)日:2011-12-06
The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS
申请人:Yao Wenqing
公开号:US20120040964A1
公开(公告)日:2012-02-16
The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.